EMProS-bio develops and commercializes specialty molecular diagnostics for migraine headache and other types of neuroinflammatory diseases. Its tests are designed to allow appropriate patient selection, stratification and management of patient treatment. EMPros’s assays incorporate both gold-standard and innovative technologies to provide highly sensitive, standardized, reliable results that support clinical development, regulatory approval, and commercialization of novel drugs in the treatment of migraine and neuroinflammation. A private company based in Aalborg, EMProS was founded by Meg Duroux and Parisa Gazerani, both senior researchers working at Aalborg University, DK.
EMProS-bio has been a part of the Accelerace accelerator program, that help startup companies accelerate and scale up their business model and finetune their companies. EMProS-bio is one of more than 500 companies that Accelerace already have accelerated.